News & AnalysisArbor Biotechnologies nets $215m Series BArbor Biotechnologies, a biotechnology company, has raised $215 million in Series B financing.ByIris Dorbian9 November 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsTechnologyBriefs